1. Development of a preclinical pharmacokinetic/ pharmacodynamic relationship for the angiogenesis inhibitor SU11248, a selective inhibitor of VEGF and PDGF receptor tyrosine kinases in clinical development;Mendel;Proc. Am. Soc. Clin. Oncol.,2002
2. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia;Fiedler;Blood,2003
3. Role of tyrosine kinase inhibitors in cancer therapy;Arora;JPET,2005
4. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668;Davis;Clin. Cancer Res.,2005
5. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis;Shaheen;Cancer Res.,1999